Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

Table 1 Clinical characteristics of patients

Characteristics	CRT alone	CRT-AC	X ²	p
Gender			4.904	0.027
Male	72	77
Female	26	12
Median age (y, range)	59 (40–70)	58 (43–70)	0.082	0.265
ECOG scoring			4.342	0.116
0	20	26
1	76	63
2	2	0
Tumor location			0.174	0.982
Cervical	12	12
Upper	40	34
Middle	38	36
Lower	8	7
Clinical T stage			0,423	0.809
T2	11	12
T3	46	38
T4	41	39
Clinical N stage			3.761	0.153
N0	18	21
N1	70	65
N2	10	3
Clinical M stage			0	0.997
M0	76	69
M1	22	20
Clinical stage			2.502	0.475
II	17	20
III	29	18
IVA	30	31
IVB	22	20
Dose (Gy, range)
GTV	61.5 (50–66)	61.5 (50–66)	0.023	0.755
CTV	50 (45–54)	50 (45–50.4)	0.081	0.282
Cycles of CC			8.294	0.016
1	34	19
2	62	61
3	2	9
Regimen of CC			0.296	0.586
PF	16	12
TP	82	77

CC concurrent chemotherapy; CRT-AC chemoradiotherapy followed with adjuvant chemotherapy; CRT concurrent chemoradiotherapy; ECOG Eastern Cooperative Oncology Group scoring; GTV gross tumor volume; CTV clinical target volume; PF platinum plus fluorouracil; TP platinum plus taxane; M1 supraclavicular lymph node metastasis

ISSN: 1748-717X